Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2012
March 18, 2013 15:23 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 18, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the fiscal year ended December 31, 2012. The net loss for 2012's twelve month...
Hemispherx Biopharma Gains Broad Treatment Expansion for Alferon N Injection(R) in Argentina
March 04, 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that ANMAT (Administracion Nacional de Medicamentos, Alimentos y...
Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
February 04, 2013 19:35 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received a Complete Response Letter from the US Food and...
FDA Advisory Committee Makes Recommendations on Ampligen (R) for Chronic Fatigue Syndrome
December 21, 2012 14:57 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 21, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced the outcome of the meeting of the Arthritis Advisory Committee...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2012
November 02, 2012 15:11 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 2, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three months ended September 30, 2012. The net comprehensive loss for the period...
Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012
October 22, 2012 08:49 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that the U.S. Food and Drug Administration ("FDA") has...
Hemispherx Biopharma Files for Treatment Expansion in Argentina for Alferon N Injection(R) for Hepatitis C
October 01, 2012 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 1, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced that the Company has filed with ANMAT (Administracion Nacional de...
Hemispherx Biopharma Announces FDA Advisory Committee Will Review Ampligen(R) for Chronic Fatigue Syndrome
September 24, 2012 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 24, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that the U.S. Food and Drug Administration ("FDA") has...
Hemispherx Biopharma Reports on Annual Stockholder Meeting
September 19, 2012 15:44 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it held its 2012 Annual Meeting of Stockholders on September 18, 2012. Final voting results will be...
Hemispherx Biopharma to Present at the Rodman and Renshaw 14th Annual Healthcare Conference
September 06, 2012 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 6, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company"), today announced that the Company will participate in the Rodman & Renshaw 14th Annual...